Eton Pharmaceuticals (ETON) Cash from Financing Activities (2019 - 2025)
Eton Pharmaceuticals (ETON) posted Cash from Financing Activities of $421000.0 for Q4 2025, up 6.85% sequentially from $394000.0 in Q1 2025, and down 98.75% YoY from $33.6 million in Q4 2024.
Eton Pharmaceuticals (ETON) Cash from Financing Activities (2019 - 2025) Analysis & Trends
Eton Pharmaceuticals has reported Cash from Financing Activities for 7 years, with the latest figure at $421000.0 in Q4 2025.
- Quarterly Cash from Financing Activities fell 98.75% year-over-year to $421000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $815000.0 (down 97.5% YoY) and the FY2025 annual result came in at $815000.0, down 97.5% from the prior year.
- Cash from Financing Activities improved to $421000.0 in Q4 2025 per ETON's latest filing, from $394000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $33.6 million in Q4 2024 and troughed at -$385000.0 in Q1 2022.
- A 5-year average of $1.8 million and a median of -$7000.0 in 2022 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities plunged 1154.29% in 2023, then soared 11519.05% in 2024.
- Over 5 years, Cash from Financing Activities stood at $68000.0 in 2021, then surged by 45.59% to $99000.0 in 2022, then plunged by 396.97% to -$294000.0 in 2023, then jumped by 11519.05% to $33.6 million in 2024, then sank by 98.75% to $421000.0 in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $421000.0, $394000.0, and $33.6 million for Q4 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Eton Pharmaceuticals | 1.65 Bn | 1.62 Bn | 25.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 421,000.00 |
| Dec 31, 2025 | 421,000.00 |
| Mar 31, 2025 | 394,000.00 |
| Mar 31, 2025 | 394,000.00 |
| Dec 31, 2024 | 33.57 Mn |
| Dec 31, 2024 | 33.57 Mn |
| Sep 30, 2024 | -385,000.00 |
| Sep 30, 2024 | -385,000.00 |
| Jun 30, 2024 | -216,000.00 |
| Jun 30, 2024 | -216,000.00 |
| Mar 31, 2024 | -378,000.00 |
| Mar 31, 2024 | -378,000.00 |
| Dec 31, 2023 | -294,000.00 |
| Dec 31, 2023 | -294,000.00 |
| Sep 30, 2023 | -369,000.00 |
| Sep 30, 2023 | -369,000.00 |
| Jun 30, 2023 | -245,000.00 |
| Jun 30, 2023 | -245,000.00 |
| Mar 31, 2023 | -49,000.00 |
| Mar 31, 2023 | -49,000.00 |